This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...
Hosted on MSN1mon
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, ZepboundLilly also announced other multibillion-dollar manufacturing expansion projects near its Indianapolis headquarters earlier this year. Eli Lilly and Co. said Thursday that it has slated more than $ ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback